• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

    4/28/25 12:00:00 PM ET
    $AZN
    $SOPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AZN alert in real time by email

    BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (NASDAQ:AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024, this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.

    SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)

    Developed in collaboration with Memorial Sloan Kettering Cancer Center, MSK-ACCESS® powered with SOPHiA DDM™ is an innovative liquid biopsy testing application designed to detect actionable genomic alterations from a single blood draw using proprietary, state-of-the-art algorithms which analyze circulating tumor DNA (ctDNA). The application supports real-time cancer monitoring and treatment selection when traditional tissue biopsies are not feasible due to cost, turnaround time, insufficient tissue, or the invasiveness of the procedure.

    The expanded rollout will continue to contribute to AstraZeneca's global real-world evidence initiatives and help further validate the clinical impact of decentralized liquid biopsy testing across diverse healthcare systems. By increasing the availability of MSK-ACCESS® powered with SOPHiA DDM™, SOPHiA GENETICS and AstraZeneca aim to understand further how liquid biopsy testing can complement solid tissue testing and, in some cases, provide greater benefit for labs and patients.  

    The announcement coincides with SOPHiA GENETICS's presentation at AACR, in which the company presented data demonstrating the robust transferability of the decentralized MSK-ACCESS® powered with SOPHiA DDMTM solution. Historically, site-to-site discordance has been a major barrier to the widespread adoption of liquid biopsy testing. SOPHiA GENETICS presented real-world data highlighting the consistent accuracy and precision of MSK-ACCESS® powered with SOPHiA DDMTM across various laboratory settings. Interim results from the multi-center study demonstrated the high analytical performance of the decentralized test in line with the original single-site test at Memorial Sloan Kettering Cancer Center in New York.

    "Our collaboration with AstraZeneca represents a significant step toward scaling next-generation oncology diagnostics globally," said Ross Muken, President, SOPHiA GENETICS. "This expanded deployment reflects the growing momentum behind liquid biopsy and our shared ambition to make these technologies more accessible and impactful worldwide."

    Visit SOPHiA GENETICS at the American Association for Cancer Research's Annual Meeting in Chicago, Illinois from April 25th–30th to learn more about how SOPHiA GENETICS is collaborating with AstraZeneca to transform patient care with data-driven medicine.

    For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn. 

    About SOPHiA GENETICS  

    SOPHiA GENETICS (NASDAQ:SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

    SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

    SOPHiA GENETICS Forward-Looking Statements: 

    This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

    Media Contact:

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-expanded-collaboration-with-astrazeneca-to-accelerate-liquid-biopsy-testing-globally-from-aacr-302439912.html

    SOURCE SOPHiA GENETICS

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $SOPH

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    SOPHiA GENETICS SA
    $SOPH
    12/18/2024$11.00Buy
    Craig Hallum
    AstraZeneca PLC
    $AZN
    11/20/2024Sell → Neutral
    UBS
    More analyst ratings

    $AZN
    $SOPH
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/20/26 6:57:38 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SOPHiA GENETICS SA

    SCHEDULE 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    2/11/26 6:02:53 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/10/26 11:55:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $SOPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

    CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three years in AMPLIFY Phase III trial AstraZeneca's CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The approval by the US Food and Drug Administration (FDA) was based on positive results from the AMPLIFY Phase III trial, which were presented at the American Society of Hematology 2024 Annual Meetin

    2/20/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

    Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca's ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER

    2/19/26 2:30:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026

    BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be availa

    2/17/26 8:00:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AZN
    $SOPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $SOPH
    Leadership Updates

    Live Leadership Updates

    View All

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

    BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

    11/5/24 6:32:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AZN
    $SOPH
    Financials

    Live finance-specific insights

    View All

    SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026

    BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be availa

    2/17/26 8:00:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AstraZeneca results: FY and Q4 2025

    Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4

    2/10/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

    Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pres

    12/2/25 9:18:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $SOPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SOPHiA GENETICS SA

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    11/13/24 3:31:21 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    2/20/24 4:55:59 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    2/14/24 11:23:25 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care